Oncological outcomes of papillary versus clear cell renal cell carcinoma in pT1 and pT2 stage: Results from a contemporary Turkish patient cohort


https://doi.org/10.4081/aiua.2023.11218
Vol. 95 No. 2 (2023)
Submitted: January 26, 2023
Accepted: February 17, 2023
Published: May 29, 2023
Kidney cancer, Renal cell carcinoma, Clear cell RCC, Papillary type RCC, Recurrence, Survival
Abstract Views: 534
PDF: 250
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Taha Cetin
    tahacetin88@gmail.com
    Izmir Bozyaka Research and Training Hospital Urology Department, Izmir; Member of Turkish Urooncology Association, Turkey. https://orcid.org/0000-0003-0330-4854
  • Serdar Celik Izmir Bozyaka Research and Training Hospital Urology Department, Izmir; Member of Turkish Urooncology Association, Turkey. https://orcid.org/0000-0003-0939-9989
  • Sinan Sozen Gazi University Faculty of Medicine Urology Department, Ankara; Member of Turkish Urooncology Association, Turkey.
  • Bulent Akdogan Hacettepe University Faculty of Medicine Urology Department, Ankara; Member of Turkish Urooncology Association, Turkey.
  • Volkan Izol Cukurova University Faculty of Medicine Urology Department, Adana; Member of Turkish Urooncology Association, Turkey.
  • Guven Aslan Dokuz Eylul University Faculty of Medicine Urology Department, Izmir; Member of Turkish Urooncology Association, Turkey.
  • Evren Suer Ankara University Faculty of Medicine Urology Department, Ankara; Member of Turkish Urooncology Association, Turkey.
  • Yildirim Bayazit Cukurova University Faculty of Medicine Urology Department, Adana; Member of Turkish Urooncology Association, Turkey. https://orcid.org/0000-0001-7598-9667
  • Nihat Karakoyunlu University of Health Sciences Dıskapi Yildirim Beyazit Research and Training Hospital Urology Department, Ankara; Member of Turkish Urooncology Association, Turkey. https://orcid.org/0000-0002-6680-9860
  • Haluk Ozen Hacettepe University Faculty of Medicine Urology Department, Ankara; Member of Turkish Urooncology Association, Turkey.
  • Sumer Baltaci Ankara University Faculty of Medicine Urology Department, Ankara; Member of Turkish Urooncology Association, Turkey.
  • Fatih Gokalp Mustafa Kemal University Tayfur Ata Sokmen Medicine Faculty Urology Department, Hatay; Member of Turkish Urooncology Association, Turkey. https://orcid.org/0000-0003-3099-3317
  • Ilker Tinay Marmara University Faculty of Medicine Urology Department, Istanbul; Member of Turkish Urooncology Association, Turkey.

Objectives: To compare overall survival (OS), recurrence free survival (RFS), and cancer-specific survival (CSS) in the long-term follow-up of T1 and T2 clear-cell-Renal Cell Carcinoma (ccRCC) and papillary Renal Cell Carcinoma (pRCC) patients, as well as to determine the risk factors for recurrence and overall mortality. Material and method: Data of patients with kidney tumors obtained from the Urologic Cancer Database - Kidney (UroCaD-K) of Turkish Urooncology Association (TUOA) were evaluated retrospectively. Out of them, patients who had pathological T1-T2 ccRCC and pRCC were included in the study. According to the two histological subtype, recurrence and mortality status, RFS, OS and CSS data were analyzed. Results: RFS, OS and CSS of pRCC and ccRCC were found to be similar. Radiological local invasion was shown to be a risk factor for recurrence in pRCC, and age was the only independent factor affecting overall mortality. Conclusions: There were no differences in survivals (RFS, OS and CSS) of patients with localized papillary and clear cell RCC. While age was the only factor affecting overall mortality, radiological local invasion was a risk factor for recurrence in papillary RCC.


Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997; 183:131-3. DOI: https://doi.org/10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G

Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166:1611-1623. DOI: https://doi.org/10.1016/S0022-5347(05)65640-6

Wagener N, Edelmann D, Benner A, et al. European Association of Urology (EAU) Young Academic Urologists (YAU) Kidney Cancer Group. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease. PLoS One. 2017;12:e0184173. DOI: https://doi.org/10.1371/journal.pone.0184173

Nguyen DP, Vertosick EA, Corradi RB, et al. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy. Urol Oncol. 2016; 34:259.e1-8. DOI: https://doi.org/10.1016/j.urolonc.2016.01.005

Steffens S, Janssen M, Roos FC, et al. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study. Eur J Cancer. 2012; 48:2347-52. DOI: https://doi.org/10.1016/j.ejca.2012.05.002

Teloken PE, Thompson RH, Tickoo SK, et al. Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol. 2009; 182:2132-6. DOI: https://doi.org/10.1016/j.juro.2009.07.019

Yoo S, You D, Jeong IG, et al. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma. J Cancer Res Clin Oncol. 2017; 143:1845-1851. DOI: https://doi.org/10.1007/s00432-017-2430-6

Kondo T, Ikezawa E, Takagi T, et al. Negative impact of papillary histological subtype in patients with renal cell carcinoma extending into the inferior vena cava: single-center experience. Int J Urol. 2013; 20:1072-7. DOI: https://doi.org/10.1111/iju.12123

Delahunt B, Eble JN, McCredie MR, et al. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol. 2001; 32:590-5. DOI: https://doi.org/10.1053/hupa.2001.24984

Pignot G, Elie C, Conquy S, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology. 2007; 69:230-5. DOI: https://doi.org/10.1016/j.urology.2006.09.052

Gudbjartsson T, Hardarson S, Petursdottir V, et al. Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients. Eur Urol. 2005; 48:593-600. DOI: https://doi.org/10.1016/j.eururo.2005.04.016

Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003; 27:612-24. DOI: https://doi.org/10.1097/00000478-200305000-00005

Jiang F, Richter J, Schraml P, et al. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol. 1998; 153:1467-73. DOI: https://doi.org/10.1016/S0002-9440(10)65734-3

Antonelli A, Tardanico R, Balzarini P, et al. Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma. Cancer Genet Cytogenet. 2010; 199:128-33. DOI: https://doi.org/10.1016/j.cancergencyto.2010.02.013

Waldert M, Haitel A, Marberger M, et al. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC. BJU Int. 2008;102:1381-4. DOI: https://doi.org/10.1111/j.1464-410X.2008.07999.x

Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005; 23:2763-71. DOI: https://doi.org/10.1200/JCO.2005.07.055

Lee WK, Lee SE, Hong SK, et al. Characteristics and prognostic value of papillary histologic subtype in nonmetastatic renal cell carcinoma in Korea: a multicenter study. Urol J. 2014; 11:1884-90.

Keegan KA, Schupp CW, Chamie K, et al. Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol. 2012; 188:391-7. DOI: https://doi.org/10.1016/j.juro.2012.04.006

Beck SD, Patel MI, Snyder ME, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol. 2004; 11:71-7. DOI: https://doi.org/10.1007/BF02524349

Simone G, Tuderti G, Ferriero M, et al. Papillary type 2 versus clear cell renal cell carcinoma: Survival outcomes. Eur J Surg Oncol. 2016; 42:1744-1750. DOI: https://doi.org/10.1016/j.ejso.2016.08.003

Kim KH, You D, Jeong IG, et al. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus. BJU Int. 2012; 11:E673-8. DOI: https://doi.org/10.1111/j.1464-410X.2012.11498.x

Yildirim Bayazit, Cukurova University Faculty of Medicine Urology Department, Adana; Member of Turkish Urooncology Association

 

 

Nihat Karakoyunlu, University of Health Sciences Dıskapi Yildirim Beyazit Research and Training Hospital Urology Department, Ankara; Member of Turkish Urooncology Association




Cetin, T., Celik, S., Sozen, S., Akdogan, B., Izol, V., Aslan, G., Suer, E., Bayazit, Y., Karakoyunlu, N., Ozen, H., Baltaci, S., Gokalp, F., & Tinay, I. (2023). Oncological outcomes of papillary <i>versus</i> clear cell renal cell carcinoma in pT1 and pT2 stage: Results from a contemporary Turkish patient cohort. Archivio Italiano Di Urologia E Andrologia, 95(2). https://doi.org/10.4081/aiua.2023.11218

Copyright (c) 2023 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC